Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Date:9/8/2009

>

                               PALATIN TECHNOLOGIES, INC.
                       Consolidated Statement of Operations Data
                                      (unaudited)


                                Year Ended June 30,     Quarter Ended June 30,
                                  2009          2008        2009         2008

    REVENUES               $11,351,774   $11,483,287  $4,227,070   $1,015,764

    OPERATING EXPENSES:
      Research and
       development          13,356,751    21,187,762   3,045,423    4,891,494
      General and
       administrative        5,296,859     6,928,295   1,415,171    1,460,066
        Total operating
         expenses           18,653,610    28,116,057   4,460,594    6,351,560

        Loss from
         operations         (7,301,836)  (16,632,770)   (233,524)  (5,335,796)

    OTHER INCOME (EXPENSE):
      Investment income        233,319     1,030,452      38,137      122,162
      Interest expense         (26,159)      (73,495)     (5,143)     (28,661)
      Gain on sale of
       property and equipment  550,968             -           -            -
        Total other income,
         net                   758,128       956,957      32,994       93,501

        Loss before income
         taxes              (6,543,708)  (15,675,813)   (200,530)  (5,242,295)
    Income tax benefit       1,741,476     1,291,444           -            -

    NET LOSS               $(4,802,232) $(14,384,369)  $(200,530) $(5,242,295)

    Basic and diluted net
     loss per common share      $(0.06)       $(0.17)     $(0.00)      $(0.06)

    Weighted average number
     of common shares
     outstanding used in
     computing basic and
     diluted net loss per
     common share           86,370,306    85,220,575  86,662,901   85,297,321

                              PALATIN TECHNOLOGIES, INC.
                            Consolidated Balan
'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Nov. 20 Cell Therapeutic...ay that the Ninth Circuit Court of Appeals reverse...hould be allowed to pursue all of its claims again...strict Court for trial. CTI filed a complaint aga...bursement consultant for CTI,s product TRISENOX, i...
(Date:11/19/2009)... 19 Omeros Corporation (...l results for the third quarter ended September 30...009, Omeros reported a net loss of $3.9 million, o....4 million, or $2.54 per share, for the same perio... 2009, the Company reported a net loss of $15.5 mi...
(Date:11/19/2009)...Pa. and WALTHAM, Mass., Nov. 19 Ar...rces find that the leading driver of antibiotic se...-spectrum activity against gram-positive and gram-...s that can cause nosocomial pneumonia, surveyed Eu...for agents that provide appropriate coverage again...
(Date:11/19/2009)... InSound is honored by latest award for revolutio...k, CA (PRWEB) November 16, 2009 -- Popular Science...uo; hearing aid from InSound Medical a winner of i...ealth category.    Chosen from...e deep in the hearing canal for up to four months ...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...ison, Wis. - Are state government information tec...ve, problematic, and time-consuming? , ,Matt Misze...cated the problems Wisconsin is having with IT con...s. He has plenty of support on that point, especia...uns, implementation delays, and outright failures ...
...ison, Wis. - GenTel BioSciences, Inc., a develo...1.2 million Phase II SBIR grant from the National ...es less painful diagnosis of respiratory allergies... mild to chronic seasonal allergies, and current d...children and senior citizens. GenTel,s protein chi...
...consin Rapids, Wis. - Cyber Defense Agency , a W...earch company, is warning that widespread use of o... military and other organizations could expose the...tacks buried deep within the millions of lines of ...ices for the U.S. government and various infrastru...
Other Biology Technology:State IT failures are not inevitable 2State IT failures are not inevitable 3State IT failures are not inevitable 4State IT failures are not inevitable 5GenTel gets federal grant to develop allergy test 2GenTel gets federal grant to develop allergy test 3Company issues warning on outsourced software 2Company issues warning on outsourced software 3
(Date:11/20/2009)...s., November 19, 2009 The estimated 4.6 million A... risk of developing respiratory symptoms due to po...tionnaire study undertaken earlier this year by in...of Veterinary Medicine. , The studywhich polled ...hat 50 percent of individuals working in barns com...
(Date:11/20/2009)...ion of a single bacterial gene into yeast, researc...therlands achieved three improvements in bioethano...re ethanol, less acetate and elimination of the ma...as published in the scientific journal Applied an...Bioethanol is made by the yeast Saccharomyces cere...
(Date:11/20/2009)...vailable in German . , In the current onlin..., Dr. Stefanie Eyerich and Dr. Kilian Eyerich toge...ondon and Istituto Dermopatico dell,Immacolata in ...epresents a milestone on the way to developing new...such as psoriasis and allergic reactions and poten...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Delft breakthrough in bioethanol production from agricultural waste 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2First Midwest Healthcare Business Intelligence 28BI 29 Summit October 27 in Minneapolis 3B International Panel to Discuss New Regulations Recession 53320 1First Midwest Healthcare Business Intelligence 28BI 29 Summit October 27 in Minneapolis 3B International Panel to Discuss New Regulations Recession 53320 2First Midwest Healthcare Business Intelligence 28BI 29 Summit October 27 in Minneapolis 3B International Panel to Discuss New Regulations Recession 53320 3First Midwest Healthcare Business Intelligence 28BI 29 Summit October 27 in Minneapolis 3B International Panel to Discuss New Regulations Recession 53320 4Dignitaries Come Together to Honor Participants in the Team Sarcoma Initiative 53318 1Dignitaries Come Together to Honor Participants in the Team Sarcoma Initiative 53318 2Dignitaries Come Together to Honor Participants in the Team Sarcoma Initiative 53318 3Dignitaries Come Together to Honor Participants in the Team Sarcoma Initiative 53318 4Natural Healers Launches 26quot 3BWellness Community Bulletin 26quot 3B 53316 1Natural Healers Launches 26quot 3BWellness Community Bulletin 26quot 3B 53316 2Natural Healers Launches 26quot 3BWellness Community Bulletin 26quot 3B 53316 3Natural Healers Launches 26quot 3BWellness Community Bulletin 26quot 3B 53316 4
... at least since the days of Bob Dylan. But now th... Michael E. Wysession, Ph.D., associate pro...ciences at Washington University in St. Louis, has... format in February. Its a sort of brainiac,s box...ct of the Earth, from its origins and composition ...
...ausing genes will be much easier and faster using ...researchers at The University of Texas at Austin. ... researcher Insuk Lee, used the gene network techn... and are involved in tumor development in the nema...s group at The Wellcome Trust Sanger Institute, th...
...sons to investigate the link between nutrition and...y will look at which nutrients are most important ...om three young offenders institutions housing male...plements on top of their normal choice of food to ...ls and essential fatty acids to meet daily guideli...
Other Biology News:Professor's video series explains all facets of Earth 2Gene discovery made easier with powerful new networking technique 2Prison study to investigate link between diet and behavior 2
Rabbit Anti-HALOPERIDOL Polyclonal Antibody, Unconjugated from AbD Serotec
Mouse Serpin A1 from R&D Systems
Rabbit Anti-SALMONELLA (GROUP ANTIGEN) Polyclonal Antibody, HRP Conjugated from AbD Serotec
beta-galactosidase Colorimetric Assay Kit from Cell Signaling Technology
Biology Products: